GlobeNewswire: iBio, Inc. Contains the last 10 of 196 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:55:20ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853011/0/en/iBio-and-AstralBio-Announce-Transformative-AI-drug-discovery-Collaboration-to-Rapidly-Develop-Novel-Antibodies-for-Obesity-and-Cardiometabolic-Diseases.html?f=22&fvtc=4&fvtv=34607iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases2024-03-27T11:00:00Z<![CDATA[– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –]]>https://www.globenewswire.com/news-release/2024/03/26/2852850/0/en/iBio-Announces-15-0-Million-Private-Placement.html?f=22&fvtc=4&fvtv=34607iBio Announces $15.0 Million Private Placement2024-03-26T23:35:11Z<![CDATA[– Purchase price of $2.85 represents a premium of 148+% to last close –]]>https://www.globenewswire.com/news-release/2024/02/26/2835048/0/en/iBio-Announces-Sale-of-Preclinical-PD-1-Agonist-Antibody-Program-to-Otsuka.html?f=22&fvtc=4&fvtv=34607iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka2024-02-26T12:45:00Z<![CDATA[– Deal includes $1 million upfront and potential future milestone payments –]]>https://www.globenewswire.com/news-release/2024/01/16/2809865/0/en/iBio-Announces-Participation-in-23rd-Annual-PepTalk-Conference.html?f=22&fvtc=4&fvtv=34607iBio Announces Participation in 23rd Annual PepTalk Conference2024-01-16T13:15:00Z<![CDATA[- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning - - VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -]]>https://www.globenewswire.com/news-release/2023/12/26/2801051/0/en/iBio-Amends-and-Extends-Maturity-of-Credit-Agreement.html?f=22&fvtc=4&fvtv=34607iBio Amends and Extends Maturity of Credit Agreement2023-12-26T12:15:00Z<![CDATA[– Extends maturity date to March 29, 2024 –]]>https://www.globenewswire.com/news-release/2023/12/05/2790859/0/en/iBio-Inc-Announces-Pricing-of-4-5-Million-Public-Offering.html?f=22&fvtc=4&fvtv=34607iBio, Inc. Announces Pricing of $4.5 Million Public Offering2023-12-05T13:00:00Z<![CDATA[BRYAN, Texas and SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The Series C Warrants to purchase up to an aggregate of 2,250,000 shares of common stock and Series D Warrants to purchase up to an aggregate of 2,250,000 shares of common stock will have an exercise price of $2.00 per share, will be exercisable immediately following the date of issuance and will expire two years and five years from the original issuance date, respectively.]]>https://www.globenewswire.com/news-release/2023/11/27/2786548/0/en/iBio-Announces-Reverse-Stock-Split.html?f=22&fvtc=4&fvtv=34607iBio Announces Reverse Stock Split2023-11-27T22:20:00Z<![CDATA[BRYAN, Texas and SAN DIEGO, Nov. 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708.]]>https://www.globenewswire.com/news-release/2023/11/01/2771164/0/en/iBio-Further-Expands-Tech-Stack-with-ShieldTx-Enhances-Immuno-Oncology-Development-Pipeline-with-Conditionally-Activated-MUC16xCD3-Bispecific.html?f=22&fvtc=4&fvtv=34607iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific2023-11-01T12:24:00Z<![CDATA[- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -]]>https://www.globenewswire.com/news-release/2023/10/10/2757444/0/en/iBio-to-Highlight-Technology-for-Advancing-Discovery-of-Bispecifics-at-Festival-of-Biologics.html?f=22&fvtc=4&fvtv=34607iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics2023-10-10T12:00:00Z<![CDATA[- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries -]]>https://www.globenewswire.com/news-release/2023/10/02/2752591/0/en/iBio-Explains-Recent-Filing-of-Registration-Statement.html?f=22&fvtc=4&fvtv=34607iBio Explains Recent Filing of Registration Statement2023-10-02T10:45:00Z<![CDATA[– No new securities are being registered under the Post-Effective Amendment – – No new securities are being registered under the Post-Effective Amendment –]]>